Perspective Therapeutics, Inc. (NYSE American: CATX) announced 2Q 2026 results, advancing programs like VMT-α-NET toward a Phase 3 study while reporting over $237 million in cash to fund operations into late 2027.
Perspective Therapeutics, Inc. (NYSE American: CATX) announced 2Q 2026 results, advancing programs like VMT-α-NET toward a Phase 3 study while reporting over $237 million in cash to fund operations into late 2027.